Skip to main content
Publications
Walley D , Twiss J , Doward L , Balp MM, Brass C, Loeffler J, Lopez P, Cai J, Cryer D, Anstee Q, Sanyal A. Patient-reported symptoms and impact in nonalcoholic steatohepatitis: an evaluation of the NASH-CHECK, a novel PROM in NASH . Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. Digital. [abstract] J Hepatol. 2020 Jan; 73:S422-3. doi: 10.1016/S0168-8278(20)33053-1
Breckons M, Doward L , McSweeney L, Balp MM, Twiss J , Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis . Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. digital. [abstract] J Hepatol. 2020 Jan; 73:S423. doi: 10.1016/S0168-8278(20)33053-1
Doward L , Balp MM, Twiss J , Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Anstee QM, Sanyal A. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis . Poster presented at the 2018 EASL International Liver Conference; April 13, 2018. Paris, France. [abstract] J Hepatol. 2018 Apr; 68(Suppl 1):S570.
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Doward LC , Balp MM, Stewart KE, Cryer D, Langford A, Twiss J , Agashivala N, Brass C, Anstee QM, Sanyal A. Exploring the patient perceived impact of non-alcoholic steatohepatitis . Poster presented at the 2017 EASL International Liver Conference; April 2017. Amsterdam, The Netherlands. [abstract] J Hepatol. 2017 Apr; 66(1 Supplement):S422-3. doi: 10.1016/S0168-8278(17)31208-4
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050